Detailed narrative
AEP Performance and Growth Strategy
Humana is seeing new sales at the high end of anticipated outcomes for AEP, driven by improved channel mix (more own distribution, high-performing partners, digital) and favorable product mix (higher sales in 4-star+ plans). The company's growth strategy focuses on maximizing customer lifetime value and NPV, prioritizing retention and stable benefit designs. Management is prepared to dynamically manage new sales volume to avoid negatively impacting member experience, including potential mitigating actions.
Stars Performance and Recovery Efforts
The bonus year '27 Stars results were disappointing but consistent with expectations and baseline planning. Humana is confident in returning to Top Quartile Stars results in bonus year '28, citing meaningful year-over-year improvement across most metrics in the current measurement year. Operational gains in Q4 2024 have continued into 2025, with 600,000 more gaps closed year-over-year, indicating steady momentum in HEDIS and patient safety metrics.
Operational Efficiency and Transformation
Humana is making progress on highly efficient operations, including a partnership with Genpact for finance capabilities and the introduction of an agentic AI platform for call centers. These initiatives are expected to generate over $100 million in savings over a few years while improving quality. This is part of a multi-year transformation focusing on tactical cost programs and longer-term operational changes.
Capital Allocation and Strategic Investments
The company completed an asset sale (Enclara Pharmacia) and is pursuing additional non-core asset divestitures to free up capital. Humana is deploying capital to strategic acquisitions, such as The Villages Health, which expands primary and specialty care services. CenterWell Pharmacy is also developing direct-to-consumer and exploring direct-to-employer opportunities, leveraging its pharmacy capabilities.
Balance Sheet and Capital Deployment
Humana's debt-to-cap ratio improved to 40.3% from 40.7% sequentially, targeting approximately 40% long-term. The company remains prudent in its near-term capital deployment, with the FY25 outlook not contemplating additional share repurchases beyond offsetting stock-based compensation dilution. Management sees opportunities for small to mid-sized provider business acquisitions given current market dislocation.
Medicaid and Duals Strategy
Humana prioritizes Medicaid business where there's a strong linkage to duals opportunities, especially with changes slated for dual integration states. The company has an industry-leading win rate in Medicaid procurements, targeting markets with dual opportunities. Dual products tend to perform well financially from the first year, and Humana is expanding into Michigan HIDE, Illinois, and South Carolina for dual-eligible populations in 2026.